Field | Sense | Antisense |
siRNA chemical modification | Cholesterol* 2-O-Methyl* Fluorouridine* Phosphorothioate | 2-O-Methyl* Phosphorothioate |
siRNA modification types | 4 | 2 |
Overall number of modifications | 8 | 8 |
Position of modifications | 1 * 1,2,3 * 15,16,17 * 19 | 16 * 9,15,16,17,18,19,21 |
Modification on sugar or base or phosphate | Phosphate; Sugar; Base; Phosphate | Sugar; Phosphate |
SMILES (Click to view structure & nomenclature) |
CC(C)CCCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C COC1C(O)OC(CO)C1O OCC1OC(C(O)C1O)N1C=C(F)C(=O)NC1=O OCC1OCC(O)C1OP(O)(S)=O |
COC1C(O)OC(CO)C1O OCC1OCC(O)C1OP(O)(S)=O |
siRNA Sequence | GAGGCUGGGAUGCCUUUTT | AAAGGCAUCCCAGCCUCCGTT |
siRNA length base-pair | 19 | 21 |
siRNA name in paper | M6 | M6 |
Biological activity | 43 percent target mRNA inhibition | |
Experiment used to check activity | Real-time PCR | |
Melting temperature (oC) | NA | |
Target gene | Bcl-2 gene | |
siRNA concentration | 33 nM | |
Cell or Organism used | HeLa B2 cells | |
Transfection method | Lipofectamine 2000 | |
Duration after transfection | 48 Hours | |
Article title | Asymmetric siRNA targeting the bcl 2 gene inhibits the proliferation of cancer cells in vitro and in vivo | |
Reference | 23135004 |